Revance Therapeutics, Inc. - Common Stock, par value $0.001 per share (RVNC)
CUSIP: 761330109
Q3 2025 13F Holders as of 30 Sep 2025
- Type / Class
- Equity / Common Stock, par value $0.001 per share
- Shares outstanding
- 104,661,494
- Total 13F shares
- 173,355
- Share change
- +173,355
- Total reported value
- $899,713
- Price per share
- $5.19
- Number of holders
- 1
- Value change
- +$899,713
- Number of buys
- 1
Quarterly Holders Quick Answers
What is CUSIP 761330109?
CUSIP 761330109 identifies RVNC - Revance Therapeutics, Inc. - Common Stock, par value $0.001 per share in SEC institutional holdings data.
Need full ownership history?
Open the full security ownership history page.
Next holder-history checks
These links keep the next click tied to holder verification, nearby quarters, or outside-13F ownership context.
- Back to full security ownership history for the broader multi-quarter picture.
- Latest 13F filings for newly reported positions across managers.
- Latest Schedule 13D/13G reports for ownership changes outside the 13F cadence.
- SEC investors directory for manager drilldown.
Explore More Reporting Periods
Jump to adjacent filing periods for faster comparison and easier crawl discovery.
Recent filing periods for CUSIP 761330109:
Top shareholders of RVNC - Revance Therapeutics, Inc. - Common Stock, par value $0.001 per share (13F + 13D/G + 3/4/5)
Grouped by holder across the latest SEC ownership disclosures. Ownership % is shown only when it is directly reported or safely comparable across share classes.
| Holder | Source | Role / Reporting | Ownership % | Shares | Holdings Value | 12M Net Δ | As of | Details |
|---|---|---|---|---|---|---|---|---|
| Teoxane SA |
13D/G
|
— |
6.2%
|
6,550,800
|
$32,335,404 | $0 | 30 Jan 2025 | |
| FRANKLIN RESOURCES INC |
13D/G
|
— |
4.6%
|
4,784,658
|
$23,617,550 | $0 | 30 Sep 2024 | |
| Palo Alto Investors LP |
13D/G
|
Patrick Lee, MD |
1.5%
|
1,611,787
|
$7,955,942 | $0 | 30 Sep 2024 | |
| Aubrey Rankin |
3/4/5
|
Director |
—
class O/S missing
|
570,004
|
$4,257,930 | — | 15 Mar 2022 | |
| Abhay Joshi |
3/4/5
|
COO, President of R&D |
—
class O/S missing
|
120,708
|
$901,689 | — | 15 Mar 2022 | |
| Dustin S. Sjuts |
3/4/5
|
President |
—
class O/S missing
|
167,550
|
$844,871 | — | 15 Mar 2024 | |
| Angus C. Russell |
3/4/5
|
Director |
—
class O/S missing
|
23,458
|
— | — | 04 Feb 2025 | |
| Carey OConnor Kolaja |
3/4/5
|
Director |
—
class O/S missing
|
23,458
|
— | — | 04 Feb 2025 | |
| Chris Nolet |
3/4/5
|
Director |
—
class O/S missing
|
23,458
|
— | — | 04 Feb 2025 | |
| Jill Beraud |
3/4/5
|
Director |
—
class O/S missing
|
23,458
|
— | — | 04 Feb 2025 | |
| Julian S. Gangolli |
3/4/5
|
Director |
—
class O/S missing
|
23,458
|
— | — | 04 Feb 2025 | |
| Olivia C. Ware |
3/4/5
|
Director |
—
class O/S missing
|
23,458
|
— | — | 04 Feb 2025 | |
| Vlad Coric |
3/4/5
|
Director |
—
class O/S missing
|
23,458
|
— | — | 04 Feb 2025 | |
| Philip J. Vickers |
3/4/5
|
Director |
—
class O/S missing
|
10,756
|
— | — | 04 May 2022 |
Institutional Holders of Revance Therapeutics, Inc. - Common Stock, par value $0.001 per share (RVNC) as of Q3 2025
| Investor | Option | Weight % | Change % | Value $ | * Price | Shares | Share Change | Activity | Report Period |
|---|
Compare Q3 2025 vs Q2 2025 Across Filers
| Investor | Q2 2025 Shares | Q3 2025 Shares | Share Diff | Share Chg % | Q2 2025 Value $ | Q3 2025 Value $ | Value Diff $ | Value Chg % |
|---|
Trend: ostatnie 8 kwartałów (+ wybrane okresy porównania).
An asterisk sign (*) next to the price indicates that the price is likely invalid.